Tags

Type your tag names separated by a space and hit enter

Hemorrhagic Cystitis after Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: Protective Effect of MESNA Continuous Infusion.
Biol Blood Marrow Transplant. 2020 Aug; 26(8):1492-1496.BB

Abstract

Hemorrhagic cystitis (HC) is an important complication after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplantation cyclophosphamide (PT-CY). Sodium 2-mercaptoethanesulfonate (MESNA) can prevent bladder injury when given with PT-CY. However, the best way to deliver MESNA is not known. This study assessed the incidence of HC after haplo-HSCT with PT-CY with 2 different methods of MESNA administration. The cumulative incidence of HC was lower in patients who received MESNA as a continuous infusion compared with those who received it as an intermittent bolus (5.6% versus 27.8%; P = .01). MESNA administration as an infusion was associated with a lower risk of developing HC (hazard ratio [HR], .19; 95% confidence interval [CI], .04 to .86; P = .02) on univariate analysis. This effect remained significant after adjustment in multivariate analysis (HR, .21; 95% CI, .04 to .88; P = .03). MESNA delivered as a continuous infusion is a simple and potentially useful way to prevent HC after PT-CY.

Authors+Show Affiliations

Hematology and Stem Cell Transplantation, Hospital Pablo Tobón Uribe, Medellín, Colombia. Electronic address: mabju@yahoo.com.Epidemiology and Public Health, Universidad CES, Medellín, Colombia.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32417488

Citation

Arango, Marcos, and Doris Cardona. "Hemorrhagic Cystitis After Haploidentical Transplantation With Post-Transplantation Cyclophosphamide: Protective Effect of MESNA Continuous Infusion." Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, vol. 26, no. 8, 2020, pp. 1492-1496.
Arango M, Cardona D. Hemorrhagic Cystitis after Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: Protective Effect of MESNA Continuous Infusion. Biol Blood Marrow Transplant. 2020;26(8):1492-1496.
Arango, M., & Cardona, D. (2020). Hemorrhagic Cystitis after Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: Protective Effect of MESNA Continuous Infusion. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, 26(8), 1492-1496. https://doi.org/10.1016/j.bbmt.2020.04.028
Arango M, Cardona D. Hemorrhagic Cystitis After Haploidentical Transplantation With Post-Transplantation Cyclophosphamide: Protective Effect of MESNA Continuous Infusion. Biol Blood Marrow Transplant. 2020;26(8):1492-1496. PubMed PMID: 32417488.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hemorrhagic Cystitis after Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: Protective Effect of MESNA Continuous Infusion. AU - Arango,Marcos, AU - Cardona,Doris, Y1 - 2020/05/15/ PY - 2020/03/21/received PY - 2020/04/24/revised PY - 2020/04/28/accepted PY - 2020/5/18/pubmed PY - 2020/5/18/medline PY - 2020/5/18/entrez KW - BK virus KW - Cyclophosphamide KW - Cystitis KW - Haploidentical KW - MESNA KW - Transplantation SP - 1492 EP - 1496 JF - Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation JO - Biol. Blood Marrow Transplant. VL - 26 IS - 8 N2 - Hemorrhagic cystitis (HC) is an important complication after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplantation cyclophosphamide (PT-CY). Sodium 2-mercaptoethanesulfonate (MESNA) can prevent bladder injury when given with PT-CY. However, the best way to deliver MESNA is not known. This study assessed the incidence of HC after haplo-HSCT with PT-CY with 2 different methods of MESNA administration. The cumulative incidence of HC was lower in patients who received MESNA as a continuous infusion compared with those who received it as an intermittent bolus (5.6% versus 27.8%; P = .01). MESNA administration as an infusion was associated with a lower risk of developing HC (hazard ratio [HR], .19; 95% confidence interval [CI], .04 to .86; P = .02) on univariate analysis. This effect remained significant after adjustment in multivariate analysis (HR, .21; 95% CI, .04 to .88; P = .03). MESNA delivered as a continuous infusion is a simple and potentially useful way to prevent HC after PT-CY. SN - 1523-6536 UR - https://www.unboundmedicine.com/medline/citation/32417488/Hemorrhagic_Cystitis_after_Haploidentical_Transplantation_with_Post-Transplantation_Cyclophosphamide:_Protective_Effect_of_MESNA_Continuous_Infusion L2 - https://linkinghub.elsevier.com/retrieve/pii/S1083-8791(20)30283-4 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.